Cancer Specific Mortality in Insulin-Treated Type 2 Diabetes Patients

Abstract

The cumulative dose exposure to insulin glargine was associated with a lower risk of cancer mortality in general, and of breast and pancreatic cancer in particular. This effect remained even after additional "fixed" cohort or propensity score analyses.